Kidney Transplantation
11 cases on pharmacologic decisions in kidney transplant recipients — induction and maintenance immunosuppression choice, conversion strategy for calcineurin-inhibitor toxicity, infection prevention and treatment, desensitization, and management of antibody-mediated rejection and recurrent disease — choose a case below to open its full multi-voice debate.
A repeat transplant candidate with a measurable donor-specific antibody and a negative crossmatch sits between two induction agents built for two different pictures of risk — and the honest answer may depend less on which drug is chosen than on when the antibody was last checked.
Three years of quietly declining graft function and a biopsy that finally names the cause reopen a question the transplant's own maintenance drug was never meant to answer: whether it is too late to switch away from it, or exactly the moment that matters.
A genuinely useful drug interaction — one some transplant programs reach for on purpose — turns into the actual argument against itself once the patient's livelihood depends on staying predictably, unimpairedly level behind the wheel.
A textbook drug-toxicity picture, appearing at the textbook moment, is still not the same thing as a confirmed diagnosis — and treating the calcineurin inhibitor as the whole story risks missing a complement-mediated process no amount of drug withdrawal will fix.
A trial that proved steroid withdrawal safe in patients just like him still leaves open how much of a modest rejection-risk increase is worth accepting on the one graft he has, when the graft itself, not the trial's five-year endpoint, is what has to last him a lifetime.
A second skin cancer in eighteen months makes the cancer-recurrence case for conversion, and early calcineurin-inhibitor injury makes the renal case for it too — but the same conversion trials that support both arguments also show real harm when the timing is wrong.
No antiviral has ever been proven to work against BK virus, which leaves immunosuppression reduction as the one treatment everyone agrees on — and a real, still-unsettled argument about whether a high enough viral load justifies reaching for more than that alone.
Her serostatus alone puts her in the category every guideline treats most aggressively — but the most recent consensus update also moved deliberately away from a single fixed duration, leaving real room to weigh her own circumstances against the standard.
A willing, available living donor and a positive crossmatch together raise a question with three genuinely different answers — treat the incompatibility with the established protocol, reach for a faster emerging one, or ask whether desensitizing against this donor at all is the right question.
A drug that targets antibody-producing plasma cells directly sounds like exactly what a case this advanced needs — until the randomized trial built to test that specific idea is put next to the mechanism that makes it sound appealing.
A first graft lost within months to recurrent disease makes a near-certain case for prophylactic treatment on paper — but the evidence for actually doing anything about it before the disease reappears is thinner than the risk itself feels like it should demand.